FIELD: biotechnology.
SUBSTANCE: invention relates to the biotechnology. Disclosed is a binding element specific for binding to TNF-alpha, including: (i) heavy chain CDR-H1, CDR-H2 and CDR-H3 variable sequences presented in SEQ ID No: 6, 7 and 8; and (ii) light chain CDR-L1, CDR-L2 and CDR-L3 variable sequences presented in SEQ ID No: 3, 4 and 5. Also disclosed is an isolated nucleic acid molecule comprising a sequence which codes the binding element. Disclosed is a method of producing said binding member. Besides, the corresponding expression vector and the host cell and compositions are presented. Invention can be used in treating inflammatory and other diseases, as well as in diagnostics.
EFFECT: disclosed is a method of treating TNFα-mediated disease and a method of detecting the presence of TNF-alpha in a biological sample.
36 cl, 4 dwg, 4 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TRISPECIFIC IL-17A, IL-17F AND OTHER PROINFLAMMATORY MOLECULES ANTIBODIES | 2016 |
|
RU2680011C2 |
| ANTIBODIES AND CHIMERIC ANTIGENIC RECEPTORS SPECIFIC TO CD19 | 2015 |
|
RU2741105C2 |
| CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
| IMMUNOCYTOCINS COMBINED THERAPY | 2012 |
|
RU2628089C2 |
| ANTI-IDIOTYPIC ANTIBODIES AND METHODS RELATED TO THEM | 2017 |
|
RU2773355C2 |
| POLYPEPTIDES FOR BONDING WITH "RECEPTOR OF ADVANCED GLYCATION ENDPRODUCTS", THEIR COMPOSITIONS AND METHODS, WHICH THEY TAKE PART IN | 2010 |
|
RU2558301C2 |
| STRUCTURES AIMED AT AFP/MHC PEPTIDE COMPLEXES AND TYPES OF THEIR USE | 2016 |
|
RU2754041C2 |
| IL-1beta-BINDING ANTIBODIES AND FRAGMENTS THEREOF | 2006 |
|
RU2518295C2 |
| ANTIBODIES AGAINST PD-1 AND THEIR USE | 2018 |
|
RU2788616C2 |
| HUMANISED ANTI-LIGHT ANTIBODIES AND USING THEM | 2010 |
|
RU2542394C2 |
